CA2553328C - Pyridinium and quinolinium derivatives - Google Patents

Pyridinium and quinolinium derivatives Download PDF

Info

Publication number
CA2553328C
CA2553328C CA2553328A CA2553328A CA2553328C CA 2553328 C CA2553328 C CA 2553328C CA 2553328 A CA2553328 A CA 2553328A CA 2553328 A CA2553328 A CA 2553328A CA 2553328 C CA2553328 C CA 2553328C
Authority
CA
Canada
Prior art keywords
compound according
hydroxyl
compound
trifluoromethyl
alkoxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2553328A
Other languages
English (en)
French (fr)
Other versions
CA2553328A1 (en
Inventor
Juan Carlos Lacal Sanjuan
Joaquin Campos Rosa
Miguel Angel Gallo Meza
Antonio Espinosa Ubeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Granada
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Granada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad de Granada filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of CA2553328A1 publication Critical patent/CA2553328A1/en
Application granted granted Critical
Publication of CA2553328C publication Critical patent/CA2553328C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA2553328A 2004-01-14 2005-01-11 Pyridinium and quinolinium derivatives Expired - Fee Related CA2553328C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200400072 2004-01-14
ES200400072A ES2237332B1 (es) 2004-01-14 2004-01-14 Derivados de piridinio y quinolinio.
PCT/ES2005/070002 WO2005068429A1 (es) 2004-01-14 2005-01-11 Derivados de piridinio y quinolinio

Publications (2)

Publication Number Publication Date
CA2553328A1 CA2553328A1 (en) 2005-07-28
CA2553328C true CA2553328C (en) 2012-05-15

Family

ID=34778265

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2553328A Expired - Fee Related CA2553328C (en) 2004-01-14 2005-01-11 Pyridinium and quinolinium derivatives

Country Status (15)

Country Link
US (1) US7781458B2 (enExample)
EP (2) EP1710236B1 (enExample)
JP (2) JP5047627B2 (enExample)
KR (1) KR101157206B1 (enExample)
CN (1) CN1910153B (enExample)
AT (1) ATE461918T1 (enExample)
BR (1) BRPI0506486A (enExample)
CA (1) CA2553328C (enExample)
DE (1) DE602005020112D1 (enExample)
DK (1) DK1710236T3 (enExample)
ES (2) ES2237332B1 (enExample)
MX (1) MXPA06007940A (enExample)
PL (1) PL1710236T3 (enExample)
PT (1) PT1710236E (enExample)
WO (1) WO2005068429A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586613B2 (en) * 2004-01-14 2013-11-19 Universidad De Granada Pyridinium and quinolinium derivatives
CA2729857A1 (en) 2008-07-04 2010-01-07 Traslational Cancer Drugs Pharma, S.L. Methods for the treatment and diagnosis of cancer
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
US20110212994A1 (en) * 2009-06-26 2011-09-01 Brian Clem Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders
WO2012041493A1 (en) * 2010-09-28 2012-04-05 Julius-Maximilians-Universität Würzburg Aminoquinolinium salts, methods of their production and their use as active agents for biotechnological and medical applications against binary toxins
EP2468259A1 (en) * 2010-12-23 2012-06-27 Traslational Cancer Drugs Pharma, S.L. Pharmaceutical compositions of pyridinium and quinolinium derivatives
BR112013032857A2 (pt) 2011-06-20 2017-01-24 Traslational Cancer Drugs Pharma S L método para prever a resposta clínica à quimioterapia em um indivíduo com câncer
EP2758395A1 (en) * 2011-09-22 2014-07-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of choline kinase
ES2472367B1 (es) * 2012-12-28 2015-06-02 Universidad De Granada Inhibidores no simétricos de colina quinasa con actividad antitumoral y antimalárica
WO2015028662A1 (en) 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis
ES2482290B1 (es) * 2014-06-05 2015-05-19 Universidad De Granada Inhibidores polares simétricos de colina cinasa con actividad antitumoral
JP6920411B2 (ja) 2016-07-25 2021-08-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのプリン及び３−デアザプリンアナログ
CN110997678B (zh) 2017-07-11 2023-02-21 内尔维亚诺医疗科学公司 作为胆碱激酶抑制剂的吡唑并喹唑啉衍生物
WO2025196502A1 (en) * 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206215A (en) * 1976-02-25 1980-06-03 Sterling Drug Inc. Antimicrobial bis-[4-(substituted-amino)-1-pyridinium]alkanes
GB1533952A (en) * 1976-02-25 1978-11-29 Sterling Drug Inc Anti-microbial bis-pyridinium compounds
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
IL89026A (en) * 1988-01-29 1993-02-21 Lilly Co Eli Substituted quinolines and cinnolines, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
ES2117950B1 (es) 1996-08-02 1999-09-16 Univ Granada Nuevos compuestos que bloquean la biosintesis de fosforilcolina y su uso como segundo mensajero en proliferacion celular.

Also Published As

Publication number Publication date
CN1910153B (zh) 2010-05-26
BRPI0506486A (pt) 2007-02-13
DK1710236T3 (da) 2010-07-12
JP2012149077A (ja) 2012-08-09
ATE461918T1 (de) 2010-04-15
PT1710236E (pt) 2010-06-18
ES2343418T3 (es) 2010-07-30
JP5047627B2 (ja) 2012-10-10
MXPA06007940A (es) 2007-01-23
US20070185170A1 (en) 2007-08-09
EP1710236A1 (en) 2006-10-11
WO2005068429A1 (es) 2005-07-28
ES2237332B1 (es) 2006-11-01
EP2085386A2 (en) 2009-08-05
KR101157206B1 (ko) 2012-07-06
PL1710236T3 (pl) 2010-08-31
HK1100441A1 (en) 2007-09-21
ES2237332A1 (es) 2005-07-16
EP1710236B1 (en) 2010-03-24
KR20060110364A (ko) 2006-10-24
US7781458B2 (en) 2010-08-24
DE602005020112D1 (de) 2010-05-06
CA2553328A1 (en) 2005-07-28
JP5619805B2 (ja) 2014-11-05
EP2085386A3 (en) 2009-10-28
CN1910153A (zh) 2007-02-07
JP2007517837A (ja) 2007-07-05

Similar Documents

Publication Publication Date Title
JP5619805B2 (ja) ピリジニウムおよびキノリニウム誘導体
Johnson et al. 2, 4-Diamino-5-benzylpyrimidines and analogs as antibacterial agents. 12. 1, 2-Dihydroquinolylmethyl analogs with high activity and specificity for bacterial dihydrofolate reductase
Abuo-Rahma et al. Design, synthesis, antibacterial activity and physicochemical parameters of novel N-4-piperazinyl derivatives of norfloxacin
US20160347715A1 (en) Toll-Like Receptor 8 Agonists
US8642765B2 (en) Azaindole-indole coupled derivatives, preparation methods and uses thereof
Jin et al. Design, synthesis, and dual evaluation of quinoline and quinolinium iodide salt derivatives as potential anticancer and antibacterial agents
Li et al. Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents
CN107151240A (zh) 一类多取代喹诺酮类化合物及其制备方法和用途
WO2017198196A1 (zh) 具有抗肿瘤活性的喹啉衍生物
CN113480543B (zh) 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用
Panda et al. New trifluoromethyl quinolone derivatives: Synthesis and investigation of antimicrobial properties
JP2007517837A5 (enExample)
US6916831B2 (en) Flavone acetic acid analogs and methods of use thereof
Digafie et al. Synthesis, Antibacterial, Antioxidant, and Molecular Modeling Studies of Novel [2, 3′‐Biquinoline]‐4‐Carboxylic Acid and Quinoline‐3‐Carbaldehyde Analogs
Siim et al. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs
CN107635991B (zh) 作为tdp2的抑制剂的呋喃并喹啉二酮
US8586613B2 (en) Pyridinium and quinolinium derivatives
Lacal et al. Derivatives of pyridine and quinoline
CN102558144A (zh) 一种芳基脲衍生物
HK1100441B (en) Derivatives of pyridine and quinoline
CN121108109A (zh) 一种靶向alk蛋白的protac化合物及其抗肿瘤应用
JP4431796B2 (ja) 新規な抗マラリア剤
RU2575646C2 (ru) Соединения, пригодные для лечения преждевременного старения и, в частности, прогерии

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180111